Therapeutic implications of fibroblast growth factor receptor inhibitors in a combination regimen for solid tumors (Review)
- Authors:
- Hong Luo
- Tao Zhang
- Peng Cheng
- Dong Li
- Oleksandr Ogorodniitchouk
- Chaimaa Lahmamssi
- Ge Wang
- Meiling Lan
-
Affiliations: Department of Oncology, General Hospital of Western Theater Command, Chengdu, Sichuan 610083, P.R. China, Institut de Cancérologie Lucien Neuwirth, 42270 Saint Priest en Jarez, France, Cancer Center, Institute of Surgical Research, Third Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing 400042, P.R. China, Cancer Center, The Third Affiliated Hospital of Chongqing Medical University (Jie Er Hospital), Chongqing 401120, P.R. China - Published online on: July 10, 2020 https://doi.org/10.3892/ol.2020.11858
- Pages: 2525-2536
This article is mentioned in:
Abstract
|
Neilson KM and Friesel R: Ligand-independent activation of fibroblast growth factor receptors by point mutations in the extracellular, transmembrane, and kinase domains. J Biol Chem. 271:25049–25057. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Itoh N and Ornitz DM: Fibroblast growth factors: From molecular evolution to roles in development, metabolism and disease. J Biochem. 149:121–130. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Funato N, Moriyama K, Shimokawa H and Kuroda T: Basic fibroblast growth factor induces apoptosis in myofibroblastic cells isolated from rat palatal mucosa. Biochem Biophys Res Commun. 240:21–26. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Dienstmann R, Rodon J, Prat A, Perez-Garcia J, Adamo B, Felip E, Cortes J, Iafrate AJ, Nuciforo P and Tabernero J: Genomic aberrations in the FGFR pathway: Opportunities for targeted therapies in solid tumors. Ann Oncol. 25:552–563. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Touat M, Ileana E, Postel-Vinay S, André F and Soria JC: Targeting FGFR signaling in cancer. Clin Cancer Res. 21:2684–2694. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Gallo LH, Nelson KN, Meyer AN and Donoghue DJ: Functions of fibroblast growth factor receptors in cancer defined by novel translocations and mutations. Cytokine Growth Factor Rev. 26:425–449. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A, et al: Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med. 2:62ra932010. View Article : Google Scholar : PubMed/NCBI | |
|
Lee HJ, Seo AN, Park SY, Kim JY, Park JY, Yu JH, Ahn JH and Gong G: Low prognostic implication of fibroblast growth factor family activation in triple-negative breast cancer subsets. Ann Surg Oncol. 21:1561–1568. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Campbell J, Ryan CJ, Brough R, Bajrami I, Pemberton HN, Chong IY, Costa-Cabral S, Frankum J, Gulati A, Holme H, et al: Large-scale profiling of kinase dependencies in cancer cell lines. Cell Rep. 14:2490–2501. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Helsten T, Elkin S, Arthur E, Tomson BN, Carter J and Kurzrock R: The FGFR landscape in cancer: Analysis of 4,853 tumors by next-generation sequencing. Clin Cancer Res. 22:259–267. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Greenman C1, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, et al: Patterns of somatic mutation in human cancer genomes. Nature. 446:153–158. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Costa R, Carneiro BA, Taxter T, Tavora FA, Kalyan A, Pai SA, Chae YK and Giles FJ: FGFR3-TACC3 fusion in solid tumors: Mini review. Oncotarget. 7:55924–55938. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Babina IS and Turner NC: Advances and challenges in targeting FGFR signalling in cancer. Nat Rev Cancer. 17:318–332. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chae YK, Ranganath K, Hammerman PS, Vaklavas C, Mohindra N, Kalyan A, Matsangou M, Costa R, Carneiro B, Villaflor VM, et al: Inhibition of the fibroblast growth factor receptor (FGFR) pathway: The current landscape and barriers to clinical application. Oncotarget. 8:16052–16074. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Suyama K and Iwase H: Lenvatinib: A promising molecular targeted agent for multiple cancers. Cancer Control. 25:10732748187893612018. View Article : Google Scholar : PubMed/NCBI | |
|
Yoon JC, Hye SK, Se HP, Kim BS, Kyoung HK, Hyo JL, Hong SS, Shin DY, Lee HY, Kim HG, et al: Phase II study of dovitinib in patients with castration-resistant prostate cancer (KCSG-GU11-05). Cancer Res Treat. 50:1252–1259. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Manchado E, Weissmueller S, Morris JP IV, Chen CC, Wullenkord R, Lujambio A, de Stanchina E, Poirier JT, Gainor JF, Corcoran RB, et al: A combinatorial strategy for treating KRAS-mutant lung cancer. Nature. 534:647–651. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kitai H, Ebi H, Tomida S, Floros KV, Kotani H, Adachi Y, Oizumi S, Nishimura M, Faber AC and Yano S: Epithelial-to-mesenchymal transition defines feedback activation of receptor tyrosine kinase signaling induced by MEK inhibition in KRAS-mutant lung cancer. Cancer Discov. 6:754–769. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Singleton KR, Hinz TK, Kleczko EK, Marek LA, Kwak J, Harp T, Kim J, Tan AC and Heasley LE: Kinome RNAi screens reveal synergistic targeting of MTOR and FGFR1 pathways for treatment of lung cancer and HNSCC. Cancer Res. 75:4398–4406. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Dai B, Yan S, Lara-Guerra H, Kawashima H, Sakai R, Jayachandran G, Majidi M, Mehran R, Wang J, Bekele BN, et al: Exogenous restoration of TUSC2 expression induces responsiveness to erlotinib in wildtype epidermal growth factor receptor (EGFR) lung cancer cells through context specific pathways resulting in enhanced therapeutic efficacy. PLoS One. 10:e01239672015. View Article : Google Scholar : PubMed/NCBI | |
|
Kim B, Wang S, Lee JM, Jeong Y, Ahn T, Son DS, Park HW, Yoo HS, Song YJ, Lee E, et al: Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy. Oncogene. 34:1083–1093. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kim SM, Kim H, Yun MR, Kang HN, Pyo KH, Park HJ, Lee JM, Choi HM, Ellinghaus P, Ocker M, et al: Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy. Oncogenesis. 5:e2412016. View Article : Google Scholar : PubMed/NCBI | |
|
Shang-Gin W and Jin-Yuan S: Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 17:382018. View Article : Google Scholar : PubMed/NCBI | |
|
Ware KE, Hinz TK, Kleczko E, Singleton KR, Marek LA, Helfrich BA, Cummings CT, Graham DK, Astling D, Tan AC and Heasley LE: A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis. 2:e392013. View Article : Google Scholar : PubMed/NCBI | |
|
Greulich H: The genomics of lung adenocarcinoma: Opportunities for targeted therapies. Genes Cancer. 1:1200–1210. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C and De Maria R: Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 15:504–514. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Justilien V, Regala RP, Tseng IC, Walsh MP, Batra J, Radisky ES, Murray NR and Fields AP: Matrix metalloproteinase-10 is required for lung cancer stem cell maintenance, tumor initiation and metastatic potential. PLoS One. 7:e350402012. View Article : Google Scholar : PubMed/NCBI | |
|
Kim HR, Kim DJ, Kang DR, Lee JG, Lim SM, Lee CY, Rha SY, Bae MK, Lee YJ, Kim SH, et al: Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. J Clin Oncol. 31:731–737. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Seo AN, Jin Y, Lee HJ, Sun PL, Kim H, Jheon S, Kim K, Lee CT and Chung JH: FGFR1 amplification is associated with poor prognosis and smoking in non-small-cell lung cancer. Virchows Arch. 465:547–558. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Tran TN, Selinger CI, Kohonen-Corish MRJ, McCaughan BC, Kennedy CW, O'Toole SA and Cooper WA: Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer. Lung Cancer. 81:462–467. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ji W, Yu Y, Li Z, Wang G, Li F, Xia W and Lu S: FGFR1 promotes the stem cell-like phenotype of FGFR1-amplified non-small cell lung cancer cells through the Hedgehog pathway. Oncotarget. 7:15118–15134. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Koole K, Brunen D, van Kempen PM, Noorlag R, de Bree R, Lieftink C, van Es RJ, Bernards R and Willems SM: FGFR1 is a potential prognostic biomarker and therapeutic target in head and neck squamous cell carcinoma. Clin Cancer Res. 22:3884–3893. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Singleton KR, Kim J, Hinz TK, Marek LA, Casás-Selves M, Hatheway C, Tan AC, DeGregori J and Heasley LE: A receptor tyrosine kinase network composed of fibroblast growth factor receptors, epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, and hepatocyte growth factor receptor drives growth and survival of head and neck squamous carcinoma cell lines. Mol Pharmacol. 83:882–893. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Pearson A, Smyth E, Babina IS, Herrera-Abreu MT, Tarazona N, Peckitt C, Kilgour E, Smith NR, Geh C, Rooney C, et al: High-level clonal FGFR amplification and response to FGFR inhibition in a translational clinical trial. Cancer Discov. 6:838–851. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Chang J, Wang S, Zhang Z, Liu X, Wu Z, Geng R, Ge X, Dai C, Liu R, Zhang Q, et al: Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer. Oncotarget. 6:2009–2022. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Schlemmer M, Bauer S, Schütte R, Hartmann J, Bokemeyer C, Hosius C and Reichardt P: Activity and side effects of imatinib in patients with gastrointestinal stromal tumors: Data from a German multicenter trial. Eur J Med Res. 16:206–212. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Javidi-Sharifi N, Traer E, Martinez J, Gupta A, Taguchi T, Dunlap J, Heinrich MC, Corless CL, Rubin BP, Druker BJ and Tyner JW: Crosstalk between KIT and FGFR3 promotes gastrointestinal stromal tumor cell growth and drug resistance. Cancer Res. 75:880–891. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Bauer S, Hartmann JT, de Wit M, Lang H, Grabellus F, Antoch G, Niebel W, Erhard J, Ebeling P, Zeth M, et al: Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer. 117:316–325. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Li F, Huynh H, Li X, Ruddy DA, Wang Y, Ong R, Chow P, Qiu S, Tam A, Rakiec DP, et al: FGFR-mediated reactivation of MAPK signaling attenuates antitumor effects of imatinib in gastrointestinal stromal tumors. Cancer Discov. 5:438–541. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Sugiura K, Ozawa S, Kitagawa Y, Ueda M and Kitajima M: Co-expression of aFGF and FGFR-1 is predictive of a poor prognosis in patients with esophageal squamous cell carcinoma. Oncol Rep. 17:557–564. 2007.PubMed/NCBI | |
|
Kim HS, Lee SE, Bae YS, Kim DJ, Lee CG, Hur J, Chung H, Park JC, Jung DH, Shin SK, et al: Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma. Oncotarget. 6:2562–2572. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Pan T, Zhong X and Cheng C: Resistance to cetuximab in EGFR-overexpressing esophageal squamous cell carcinoma xenografts due to FGFR2 amplification and overexpression. J Pharmacol Sci. 126:77–83. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Luo H, Quan J, Xiao H, Luo J, Zhang Q, Pi G, Ye Y, He R, Liu Y, Su X, Zhao L and Wang G: FGFR inhibitor AZD4547 can enhance sensitivity of esophageal squamous cell carcinoma cells with epithelial-mesenchymal transition to gefitinib. Oncol Rep. 39:2270–2278. 2018.PubMed/NCBI | |
|
Pinter M and Peck-Radosavljevic M: Review article: Systemic treatment of hepatocellular carcinoma. Aliment Pharmacol Ther. 48:598–609. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kaposi-Novak P, Lee JS, Gòmez-Quiroz L, Coulouarn C, Factor VM and Thorgeirsson SS: Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest. 116:1582–1595. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
You H, Ding W, Dang H, Jiang Y and Rountree CB: c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology. 54:879–889. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Jo JC, Choi EK, Shin JS, Moon JH, Hong SW, Lee HR, Kim SM, Jung SA, Lee DH, Jung SH, et al: Targeting FGFR pathway in human hepatocellular carcinoma: Expressing pFGFR and pMET for antitumor activity. Mol Cancer Ther. 14:2613–2622. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Scheller T, Hellerbrand C, Moser C, Schmidt K, Kroemer A, Brunner SM, Schlitt HJ, Geissler EK and Lang SA: mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma. Br J Cancer. 112:841–580. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Burbridge MF, Bossard CJ, Saunier C, Fejes I, Bruno A, Léonce S, Ferry G, Da Violante G, Bouzom F, Cattan V, et al: S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab. Mol Cancer Ther. 12:1749–1762. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Feng S, Shao L, Yu W, Gavine P and Ittmann M: Targeting fibroblast growth factor receptor signaling inhibits prostate cancer progression. Clin Cancer Res. 18:3880–3888. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Feng S, Shao L, Castro P, Coleman I, Nelson PS, Smith PD, Davies BR and Ittmann M: Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors. Oncotarget. 8:6179–6192. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ibrahim N and Haluska FG: Molecular pathogenesis of cutaneous melanocytic neoplasms. Annu Rev Pathol. 4:551–579. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Beenken A and Mohammadi M: The FGF family: Biology, pathophysiology and therapy. Nat Rev Drug Discov. 8:235–253. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Metzner T, Bedeir A, Held G, Peter-Vörösmarty B, Ghassemi S, Heinzle C, Spiegl-Kreinecker S, Marian B, Holzmann K, Grasl-Kraupp B, et al: Fibroblast growth factor receptors as therapeutic targets in human melanoma: Synergism with BRAF inhibition. J Invest Dermatol. 131:2087–2095. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
André F, Bachelot T, Campone M, Dalenc F, Perez-Garcia JM, Hurvitz SA, Turner N, Rugo H, Smith JW, Deudon S, et al: Targeting FGFR with dovitinib (TKI258): Preclinical and clinical data in breast cancer. Clin Cancer Res. 19:3693–3702. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Issa A, Gill JW, Heideman MR, Sahin O, Wiemann S, Dey JH and Hynes NE: Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models. Breast Cancer Res. 15:R82013. View Article : Google Scholar : PubMed/NCBI | |
|
Holdman XB, Welte T, Rajapakshe K, Pond A, Coarfa C, Mo Q, Huang S, Hilsenbeck SG, Edwards DP, Zhang X and Rosen JM: Upregulation of EGFR signaling is correlated with tumor stroma remodeling and tumor recurrence in FGFR1-driven breast cancer. Breast Cancer Res. 17:1412015. View Article : Google Scholar : PubMed/NCBI | |
|
McConechy MK, Ding J, Cheang MC, Wiegand K, Senz J, Tone A, Yang W, Prentice L, Tse K, Zeng T, et al: Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol. 228:20–30. 2012.PubMed/NCBI | |
|
Cancer Genome Atlas Research Network, . Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, et al: Integrated genomic characterization of endometrial carcinoma. Nature. 497:67–73. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Gozgit JM, Squillace RM, Wongchenko MJ, Miller D, Wardwell S, Mohemmad Q, Narasimhan NI, Wang F, Clackson T and Rivera VM: Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models. Cancer Chemother Pharmacol. 71:1315–1323. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Packer LM, Geng X, Bonazzi VF, Ju RJ, Mahon CE, Cummings MC, Stephenson SA and Pollock PM: PI3K inhibitors synergize with FGFR inhibitors to enhance antitumor responses in FGFR2mutant endometrial cancers. Mol Cancer Ther. 16:637–648. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Hall TG, Yu Y, Eathiraj S, Wang Y, Savage RE, Lapierre JM, Schwartz B and Abbadessa G: Preclinical activity of ARQ 087, a novel inhibitor targeting FGFR dysregulation. PLoS One. 11:e01625942016. View Article : Google Scholar : PubMed/NCBI | |
|
Chilà R, Hall GT, Abbadessa G, Broggini M and Damia G: Multi-chemotherapeutic schedules containing the pan-FGFR inhibitor ARQ 087 are safe and show antitumor activity in different xenograft models. Transl Oncol. 10:153–157. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Bestvina CM and Fleming GF: Chemotherapy for endometrial cancer in adjuvant and advanced disease settings. Oncologist. 21:1250–1259. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Byron SA, Loch DC and Pollock PM: Fibroblast growth factor receptor inhibition synergizes with paclitaxel and doxorubicin in endometrial cancer cells. Int J Gynecol Cancer. 22:1517–1526. 2012.PubMed/NCBI | |
|
Meng X, Dizon DS, Yang S, Wang X, Zhu D, Thiel KW and Leslie KK: Strategies for molecularly enhanced chemotherapy to achieve synthetic lethality in endometrial tumors with mutant p53. Obstet Gynecol Int. 2013:8281652013. View Article : Google Scholar : PubMed/NCBI | |
|
Cha HJ, Choi JH, Park IC, Kim CH, An SK, Kim TJ and Lee JH: Selective FGFR inhibitor BGJ398 inhibits phosphorylation of AKT and STAT3 and induces cytotoxicity in sphere-cultured ovarian cancer cells. Int J Oncol. Mar 15–2017.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI | |
|
Schelch K, Hoda MA, Klikovits T, Münzker J, Ghanim B, Wagner C, Garay T, Laszlo V, Setinek U, Dome B, et al: Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy. Am J Respir Crit Care Med. 190:763–772. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Liu R, Li J, Xie K, Zhang T, Lei Y, Chen Y, Zhang L, Huang K, Wang K, Wu H, et al: FGFR4 promotes stroma-induced epithelial-to-mesenchymal transition in colorectal cancer. Cancer Res. 73:5926–5935. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Roidl A, Berger HJ, Kumar S, Bange J, Knyazev P and Ullrich A: Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation. Clin Cancer Res. 15:2058–2066. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Turkington RC, Longley DB, Allen WL, Stevenson L, McLaughlin K, Dunne PD, Blayney JK, Salto-Tellez M, Van Schaeybroeck S and Johnston PG: Fibroblast growth factor receptor 4 (FGFR4): A targetable regulator of drug resistance in colorectal cancer. Cell Death Dis. 5:e10462014. View Article : Google Scholar : PubMed/NCBI | |
|
Verstraete M, Debucquoy A, Gonnissen A, Dok R, Isebaert S, Devos E, McBride W and Haustermans K: In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer. BMC Cancer. 15:9462015. View Article : Google Scholar : PubMed/NCBI | |
|
Ahmed MA, Selzer E, Dörr W, Jomrich G, Harpain F, Silberhumer GR, Müllauer L, Holzmann K, Grasl-Kraupp B, Grusch M, et al: Correction: Fibroblast growth factor receptor 4 induced resistance to radiation therapy in colorectal cancer. Oncotarget. 10:5385–5386. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ader I, Delmas C, Skuli N, Bonnet J, Schaeffer P, Bono F, Cohen-Jonathan-Moyal E and Toulas C: Preclinical evidence that SSR128129E-a novel small-molecule multi-fibroblast growth factor receptor blocker-radiosensitises human glioblastoma. Eur J Cancer. 50:2351–2359. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Karlsson AK and Saleh SN: Checkpoint inhibitors for malignant melanoma: A systematic review and meta-analysis. Clin Cosmet Investig Dermatol. 10:325–339. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Giroux Leprieur E, Dumenil C, Julie C, Giraud V, Dumoulin J, Labrune S and Chinet T: Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges. Eur J Cancer. 78:16–23. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, et al: Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial. Lancet Oncol. 18:312–322. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, et al: Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 377:1824–1835. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, et al: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 377:1919–1929. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Yost KE, Satpathy AT, Wells DK, Qi Y, Wang C, Kageyama R, McNamara KL, Granja JM, Sarin KY, Brown RA, et al: Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat Med. 25:1251–1259. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Liu X and Cho WC: Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer. Clin Transl Med. 6:72017. View Article : Google Scholar : PubMed/NCBI | |
|
Kroemer G, Galluzzi L, Kepp O and Zitvogel L: Immunogenic cell death in cancer therapy. Annu Rev Immunol. 31:51–72. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Sweis RF, Spranger S, Bao R, Paner GP, Stadler WM, Steinberg G and Gajewski TF: Molecular drivers of the Non-T-cell-inflamed tumor microenvironment in urothelial bladder cancer. Cancer Immunol Res. 4:563–568. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Li P, Huang T, Zou Q, Liu D, Wang Y, Tan X, Wei Y and Qiu H: FGFR2 promotes expression of PD-L1 in colorectal cancer via the JAK/STAT3 signaling pathway. J Immunol. 202:3065–3075. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Palakurthi S, Kuraguchi M, Zacharek SJ, Zudaire E, Huang W, Bonal DM, Liu J, Dhaneshwar A, DePeaux K, Gowaski MR, et al: The combined effect of FGFR inhibition and PD-1 blockade promotes tumor-intrinsic induction of antitumor immunity. Cancer Immunol Res. 7:1457–1471. 2019. View Article : Google Scholar : PubMed/NCBI |
